首页 > 市场调查报告书 > 製药

药物开发

市场调查报告书

商品编码

1624411

药物发现服务市场：依流程、类型、药物类型、治疗领域和地区划分，2024-2031 年

Drug Discovery Services Market By Process, Type, Drug Type, Therapeutic Area, & Region for 2024-2031

出版日期: 2024年10月03日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2024-2031 年药物发现服务市场评估

随着对创新治疗和生物技术突破的需求不断增长，製药公司越来越多地转向外包，以降低与研发相关的成本并加快新药的上市时间，这推动了药物发现服务市场的发展。据 Verified Market Research 分析师称，药物发现服务市场预计到 2024 年将突破约 128.2 亿美元，并在预测期内达到 287.1 亿美元的估值。

基因组学和蛋白质组学的快速发展以及药物研发支出的增加正在推动药物发现服务市场。因此，2024年至2031年市场将以11.70%的复合年增长率成长。

药物发现服务市场定义/概述

药物发现服务是由专业合约研究组织 (CRO) 进行的外包研究和开发业务，以识别和开发新化合物。这些服务包括广泛的活动，包括标靶识别、分析开发、高通量筛选、先导化合物优化和临床试验。

此外，药物发现服务具有广泛的应用，包括加速新药开发、提供先进技术和专业知识、简化新药研究方法以及显着降低新药上市所需的成本和时间。这些服务对于希望简化研发工作、降低风险并专注于核心优势，同时利用 CRO 的专业技能和资源的製药公司至关重要。

增加研发投入将如何推动市场成长？

在大量投资的支持下，製药业正在加大对研发的投入，这是主要的驱动力。这些投资旨在开发创新疗法，以满足未满足的医疗需求，特别是在肿瘤学和神经学领域。随着全球慢性病发病率的上升需要持续创新，製药公司正在将部分药物发现服务外包给专业提供者，以提高效率和创新。

高通量筛选、生物资讯学和基因组学方面的技术进步正在推动药物发现服务市场。这些技术能够以比现有方法更便宜和更快的速度快速筛选大型化学库。此外，人工智慧和机器学习在预测药物行为、优化药物设计和识别可行的治疗候选药物、减少药物开发阶段相关的时间和成本方面变得越来越重要。

此外，大型製药和生物技术公司越来越多地透过策略联盟和外包来利用 CRO 的专业知识和先进技术。外包药物发现使公司能够专注于核心竞争力，有效控製成本并加快新疗法的上市时间。这种方法对于没有内部资源进行大规模药物开发活动的中小型生技公司尤其重要。

影响药物发现服务市场的主要课题有哪些？

药物发现是一项昂贵且高风险的事业，新疗法的开发耗资数十亿美元，而且往往需要 10 年以上的时间。失败率很高，尤其是在早期阶段，阻碍了投资并危及专案的财务可行性。这些费用和风险对于不具备大型製药公司财力的中小企业来说尤其沉重。

此外，在竞争激烈的药物发现领域，保护智慧财产权 (IP) 至关重要。然而，管理智慧财产权很困难，尤其是当涉及许多合作伙伴时，就像外包药物发现研究计画的情况一样。智慧财产权所有权和专利权可能会发生衝突，导致法律问题并阻碍新药的开发和商业化。

The growing trend of outsourcing by pharmaceutical companies to decrease costs associated with research and development and speed up time-to-market for new pharmaceuticals, along with the growing need for innovative therapies and biotechnology breakthroughs, are driving the drug discovery services market. According to the analyst from Verified Market Research, the drug discovery services market is estimated to reach a valuation of USD 28.71 Billion over the forecast subjugating around USD 12.82 Billion valued in 2024.

The rapid developments in genomics and proteomics, together with increased spending in pharmaceutical R&D, are driving the drug discovery services market, as is the requirement for specialized knowledge in drug development procedures. It enables the market to grow at aCAGR of 11.70% from 2024 to 2031.

Drug Discovery Services Market: Definition/ Overview

Drug discovery services are the outsourced research and development activities performed by specialist contract research organizations (CROs) to identify and develop new pharmaceutical compounds. These services encompass a wide range of operations, including target identification, assay development, high-throughput screening, hit-to-lead optimization, and clinical testing.

Furthermore, drug discovery services have a wide range of applications, including accelerating the development of new medications, providing access to advanced technologies and expertise, improving the efficiency of drug research processes, and significantly lowering the costs and time required to bring new drugs to market. These services are critical for pharmaceutical companies looking to streamline their R&D efforts, reduce risks, and focus on core strengths while harnessing the specialized skills and resources of CROs.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will Increase in R&D Investments Drive the Growth of the Market?

The pharmaceutical industry's rising commitment to R&D, backed by significant investments, is a primary driver. These investments are intended to develop innovative therapeutics to treat unmet medical needs, particularly in oncology and neurology. The increased global frequency of chronic diseases needs ongoing innovation, prompting pharmaceutical companies to outsource portions of their drug discovery services to specialist service providers, therefore increasing efficiency and innovation.

Technological improvements in high-throughput screening, bioinformatics, and genomics are driving the drug discovery services market. These technologies enable the rapid screening of large chemical libraries at cheaper prices and faster rates than existing approaches. Furthermore, AI and machine learning are becoming increasingly important in predicting drug behavior, optimizing drug design, and identifying viable therapeutic candidates, thus decreasing the time and cost associated with drug development phases.

Furthermore, big pharma and biotech businesses are increasingly leveraging CROs' specialized knowledge and advanced technology through strategic cooperation and outsourcing. Outsourcing drug discovery enables businesses to focus on core capabilities, effectively control costs, and reduce time to market for new treatments. This method is especially important for smaller biotech companies that lack the internal resources to perform large-scale drug development activities.

What are the Primary Challenges Impacting the Drug Discovery Services Market?

Drug discovery is an expensive and high-risk enterprise, with the development of a new treatment frequently costing billions of dollars and taking more than a decade. The failure rate is particularly high in the early phases, discouraging investment and putting the project's financial viability at risk. These expenses and hazards are especially onerous for smaller businesses that lack the financial resources of larger pharmaceutical enterprises.

Furthermore, protecting intellectual property (IP) is critical in the competitive world of drug discovery. However, managing IP rights is difficult, especially when numerous partners are involved, as is common in outsourced drug research projects. Conflicts over intellectual property ownership and patent rights may arise, resulting in legal issues and impeding the development and commercialization of novel drugs.

Category-Wise Acumens

What are the Factors Supporting the Dominance of Small Molecules in the Market?

According to VMR analysis, the small molecules segment is estimated to hold the largest market share in the drug type segment during the forecast period. Small-molecule drugs are typically less expensive to manufacture and scale than biologics. They can be generated in huge quantities using chemical procedures, making them more easily produced and distributed. Because of their low cost, small molecules are especially appealing to pharmaceutical businesses seeking to optimize their return on investment.

Small molecules have a lengthy history in the pharmaceutical industry, thus there are well-established regulatory channels for their development and approval. This familiarity streamlines medication discovery, decreases regulatory approval uncertainty, and shortens time-to-market, making them a popular choice among pharmaceutical corporations.

Furthermore, small molecules easily permeate cells and influence a wide range of biological targets, making them useful for treating a variety of disorders, both chronic and acute. This broad applicability bolsters ongoing research and development efforts, allowing them to maintain their lead in the drug discovery services market.

How does Oncology Propel the Growth of the Drug Discovery Services Market?

The oncology segment is estimated to dominate the drug discovery services market during the forecast period. The global rise in cancer incidence is a significant motivator for the emphasis on oncology in drug discovery. As cancer remains the biggest cause of death worldwide, there is a strong desire for novel and more effective cancer treatments. This need encourages pharmaceutical companies and research organizations to engage extensively in oncology research, resulting in the growth of this market segment.

The evolution of precision medicine, particularly in oncology, has had a substantial impact on medication discovery. Advances in genetic sequencing and molecular diagnostics enable more precise and individualized cancer treatments. This emphasis on unique patient profiles and tumor genetics has moved drug research efforts toward more personalized solutions, improving the efficacy and success rates of oncology drugs.

Furthermore, oncology has one of the most extensive drug development pipelines in all therapeutic fields. The continual discovery of new targets and routes for cancer treatment drives continued research and development. Also, the high likelihood of market approval and commercial success for oncology medications encourages investment in this sector, reinforcing its market share domination in drug discovery services.

Country/Region-wise Acumens

How Does the Rising Biopharmaceutical Sector Drive the Market in the Asia Pacific?

According to VMR analyst, North America is estimated to dominate the drug discovery services market during the forecast period. North America has a highly developed biopharmaceutical sector, with the United States dominating in terms of innovation, drug development, and market approvals. This region is home to several of the world's leading pharmaceutical and biotech companies, which continue to invest in medication discovery and development. This climate promotes robust R&D activity, attracting large investments and partnerships to propel the market ahead.

Furthermore, the presence of advanced research infrastructures, such as world-class universities, research institutes, and cutting-edge laboratories, facilitates large-scale drug development initiatives. North America receives major government and private financing for therapeutic research in fields such as oncology, neurology, and cardiovascular disease, which is crucial to the continued discovery of new drugs.

What are the Primary Factors Driving the Drug Discovery Services in Asia Pacific?

The Asia Pacific region is estimated to exhibit the highest growth within the drug discovery services market during the forecast period. Many countries in the Asia-Pacific region are experiencing rapid economic growth and higher healthcare spending. As these economies flourish, more resources are directed toward healthcare, including investments in innovative medical treatments and research centers. This economic development promotes the growth of the pharmaceutical and biotechnology sectors, increasing demand for drug discovery services.

Furthermore, the Asia Pacific region is experiencing an increase in the prevalence of chronic diseases such as diabetes, cardiovascular disease, and cancer, which is being driven by changing lifestyles and an aging population. This increase in disease prevalence is driving up the need for innovative and effective treatment medications, strengthening the regional drug discovery services market.

Competitive Landscape

The competitive landscape of the drug discovery services market is characterized by a wide range of vendors providing specialized services at various stages of the drug development pipeline. Furthermore, there is a growing trend toward customization and tailored service models to meet the individual needs of clients, which adds to the competitiveness.

Some of the prominent players operating in the drug discovery services market include:

Abbott Laboratories, Inc.

Advinus Therapeutics

Agilent Technologies Ubiquigent

Albany Molecular Research, Inc.

AstraZeneca PLC

Aurigene

Bayer AG

Charles River Laboratories International

ChemBridge Corporation

Covance

Latest Developments

In February 2023, Charles River Laboratories signed a multi-program agreement with Pioneering Medicines, a Flagship Pioneering (US) initiative, to use its Logica Al platform for small-molecule drug discovery.

In February 2023, Evotec SE and Related Sciences signed a multi-target drug discovery deal. The two firms sought to choose, research, and develop precisely targeted medications to address unmet patient needs.

In January 2023, Charles River Laboratories purchased SAMDI Tech, Inc., which provides label-free HTS solutions for drug discovery research. The acquisition provided CRL with experience in label-free HTS MS platforms and resulted in a broad library of drug discovery options.

1 INTRODUCTION OF DRUG DISCOVERY SERVICES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 DRUG DISCOVERY SERVICES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 DRUG DISCOVERY SERVICES MARKET, BY PROCESS

5.1 Overview
5.2 Target Selection
5.3 Target Validation
5.4 Hit-To-Lead Identification
5.5 Lead Optimization
5.6 Candidate Validation

6 DRUG DISCOVERY SERVICES MARKET, BY TYPE

6.1 Overview
6.2 Medicinal Chemistry Services
6.3 Biology Services
6.4 Drug Metabolism and Pharmacokinetics (DMPK)
6.5 Market, by Drug Type
6.6 Small- molecule Drugs
6.7 Biologic Drugs

7 GLOBAL DRUG DISCOVERY MARKET, BY DRUG TYPE

7.1 Overview
7.2 Small Molecule Drugs
7.3 Biologic Drugs

8 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA

8.1 Overview
8.2 Oncology
8.3 Neurology
8.4 Infectious and Immune System Diseases
8.5 Digestive System Diseases
8.6 Cardiovascular Diseases
8.7 Other Therapeutic Areas

9 DRUG DISCOVERY SERVICES MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East

10 DRUG DISCOVERY SERVICES MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Abbott Laboratories Inc.
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Advinus Therapeutics
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Agilent Technologies Ubiquigent
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Albany Molecular Research Inc.
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 AstraZeneca PLC
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Aurigene
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Bayer AG
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Charles River Laboratories International
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 ChemBridge Corporation
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Covance
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments

12 Appendix

12.1 Related Research

02-2729-4219

+886-2-2729-4219

License/价格

药物发现服务市场：依流程、类型、药物类型、治疗领域和地区划分，2024-2031 年

Drug Discovery Services Market By Process, Type, Drug Type, Therapeutic Area, & Region for 2024-2031

2024-2031 年药物发现服务市场评估

增加研发投入将如何推动市场成长？

影响药物发现服务市场的主要课题有哪些？

目录

第1章 药物发现服务市场简介

第 2 章执行摘要

第3章 验证市场研究研究方法

第4章 药物发现服务市场展望

第5章药物发现服务市场：依流程

第6章药物发现服务市场：按类型

第7章 全球药物发现市场：依药物类型

第8章药物发现服务市场：依治疗领域

第9章药物发现服务市场：按地区

第10章 药物发现服务市场竞争态势

第11章 公司简介

第12章附录

Drug Discovery Services Market Valuation - 2024-2031